• Publications
  • Influence
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6
We used human liver microsomes (HLMs) and recombinant cytochromes P450 (P450s) to identify the routes of efavirenz metabolism and the P450s involved. In HLMs, efavirenz undergoes primary oxidativeExpand
  • 557
  • 51
  • PDF
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.
Samir K. Gupta, Joseph A. Eustace, Jonathan A. Winston, Ivy I. Boydstun, Tejinder S. Ahuja, Rudolph A. Rodriguez, Karen T. Tashima, Michelle Roland, Nora Franceschini, Frank J. Palella, Jeffrey L.Expand
  • 608
  • 43
  • PDF
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
The human cytochromes P450 (P450) CYP3A contribute to the biotransformation of 50% of oxidatively metabolized drugs. The predominant hepatic form is CYP3A4, but recent evidence indicates that CYP3A5Expand
  • 405
  • 42
  • PDF
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
To assess the relative contribution of intestinal and hepatic CYP3A inhibition to the interaction between the prototypic CYP3A substrates midazolam and clarithromycin.
  • 403
  • 35
An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.
An in vitro model is proposed to account for the clinically observed inhibition of cytochrome P450 (CYP) 3A that results from administration of clarithromycin, fluoxetine, or diltiazem. Rates forExpand
  • 271
  • 33
  • PDF
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
  • Y. Wang, D. Jones, S. Hall
  • Chemistry, Medicine
  • Drug metabolism and disposition: the biological…
  • 1 February 2004
Verapamil inhibition of CYP3A activity results in many drug-drug interactions with CYP3A substrates, but the mechanism of inhibition is unclear. The present study showed that verapamil enantiomersExpand
  • 195
  • 33
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants.
The pregnane X receptor (PXR)/steroid and xenobiotic receptor (SXR) transcriptionally activates cytochrome P4503A4 (CYP3A4) when ligand activated by endobiotics and xenobiotics. We cloned the humanExpand
  • 285
  • 32
  • PDF
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
The capabilities of cytochrome P4503A4 (CYP3A4), CYP3A5, and fetal hepatic microsomes containing CYP3A7 to metabolize midazolam were investigated using human hepatic microsomes and purified CYP3A4Expand
  • 398
  • 27
The Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo
Echinacea is a widely available over‐the‐counter herbal remedy. Tinctures of echinacea have been shown to inhibit cytochrome P450 (CYP) in vitro. The effect of echinacea (Echinacea purpurea root) onExpand
  • 286
  • 21
The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity
St John's wort(Hypericum perforatum) is a popular over‐the‐counter dietary supplement and herbal remedy that has been implicated in drug interactions with substrates of several cytochrome P450 (CYP)Expand
  • 363
  • 16